B2BROKER
B2Broker is excited to introduce White Label cTrader, a new ready-made platform solution. Using the new product, brokers can access a wide range of features offered by the cTrader platform that can enhance their business growth and offer their customers comprehensive trading services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220908005100/en/
B2Broker Adds cTrader to Its White Label Platform Solutions (Graphic: Business Wire)
About cTrader White Label
White Label cTrader offers a high-end solution that is fully customizable to match your brand. The solution's wide range of features makes it appealing to both institutions and retail clients.
White Label cTrader has everything businesses need, with B2Broker taking care of integration, customer support, and more. Liquidity, licensing, and many other features are already in the package.
cBroker
cBroker is a back-office tool that facilitates the management of trade inquiries and customer accounts. It tracks all the data flowing through the system, providing complete control over your business.
cTrader Copy
With cTrader Copy, brokers can allow their clients to copy other traders' deals and provide their own strategies. cTrader Copy lets customers easily choose assets, investment amounts, and risk levels that suit their needs.
Open API
With the cTrader open API, building new tools or integrating existing ones is a breeze. Create an ideal user interface by customizing existing ones (like TradingView) or designing your own. Technical analysis indicators, graphics, and labels are customizable for a perfect trading experience.
Prime of Prime Liquidity Pool
Prime of Prime Liquidity Pool allows brokers to access some of the best prices for financial instruments. Thanks to Tier 1 liquidity, traders can access over a thousand instruments, including 110 FX symbols and 150 crypto CFDs, spanning many asset classes — Forex, metals, commodities, indices, cryptocurrencies, equities, and ETFs.
B2Broker and cTrader
B2Broker's White Label cTrader solution offers a complete brokerage business package for both startups and established companies.
"cTrader is a well-known platform with a proven track record of success, and it is used by all the market's top brokers. A quick search on the Appstore for cTrader will reveal all the major companies that use this platform.
We believe that in today's ultra-competitive markets, every broker must offer a wide variety of trading platforms to its clients. Otherwise, the broker would lose clients who wish to trade on the cTrader platform. In addition to the traditional trading capabilities provided by the MT platform, cTrader will almost certainly attract a new category of traders and investors.
When it comes to managing your crypto brokerage, and its algo capabilities, cTrader is one of the top solutions on the market.
Since 2021, we have been seeing a growing demand for cTrader among cryptocurrency brokers. Since many cTrader brokers use our liquidity offering, we decided to open a whole new world for brokers that want to grow more sophisticated and cater to traders' needs, rather than requiring them to use a single platform," B2Broker CEO Arthur Azizov.
White Label cTrader will have even more updates soon. With more benefits and features on the way, B2Broker is sure to continue impressing the fintech community with its innovative solutions!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005100/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
